Research from Emory University School of Medicine says that isolating cells from a patient's blood or bone marrow that nourish blood vessels may be a safer and less arduous route to treatment of cardiovascular disease than obtaining rare stem cells.
In recent clinical trials, doctors in several countries have tested the ability of a patient's bone marrow cells to repair damage, such as heart attacks and peripheral artery disease, created by problems of blood flow.
"The focus has been on stem cells, but it looks like the main beneficial effects come from transplanted cells' ability to support the growth of nearby blood vessels," says senior author Young-sup Yoon, MD, PhD, associate professor of medicine (cardiology) at Emory University School of Medicine. "Based on this idea, we wanted to identify a population of cells enriched with the capacity to regenerate blood vessels."
The blood vessel-repairing properties of selected cells from human blood were described in the Aug. 10 issue of the
Journal of the American College of Cardiology, with a related paper on cells derived from mouse bone marrow published online July 15 by the journal
Circulation Research.
The first author of the JACC paper is postdoctoral fellow Sung-Whan Kim, PhD.The first author of the
Circulation Research paper is Hyongbum Kim, MD, PhD, now an assistant professor in Korea.
Yoon's team focused on the molecule CD31, also known as platelet endothelial cell adhesion molecule-1 or PECAM-1, because of its presence on endothelial cellsthe cells that form the inner lining of blood vessels. In experiments with donated blood from human volunteers or mouse bone marrow cells, the researchers showed that cells with CD31 on their surfaces secrete hormones that support the growth of blood vessels.